Zevra Therapeutics (ZVRA) Preferred Stock Liabilities (2014)

Zevra Therapeutics (ZVRA) reported Preferred Stock Liabilities of $24.2 million for Q4 2014.

Zevra Therapeutics (ZVRA) Preferred Stock Liabilities (2014) Analysis & Trends

Zevra Therapeutics has reported Preferred Stock Liabilities for 1 years, with the latest figure at $24.2 million in Q4 2014.

For the quarter ending Q4 2014, Preferred Stock Liabilities changed N/A year-over-year to $24.2 million; the trailing twelve-month figure through Dec 2014 stood at $24.2 million (changed N/A YoY), and the FY2014 full-year result was $24.2 million, up 630.67% from the prior year.
Preferred Stock Liabilities for Q4 2014 stood at $24.2 million.
The five-year high for Preferred Stock Liabilities was $24.2 million in Q4 2014, with the low at $24.2 million in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn	-
9	Abivax	95.45 Bn	95.45 Bn	-	-
10	Zevra Therapeutics	796.95 Mn	596.33 Mn	34.30 Mn	-

Download Data

Date	Value
Dec 31, 2014	24.21 Mn